The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders

Nutritional Neuroscience

Volumn 13, Issue 2, 2010, Pages 87-100

  Whiteley, Paul ^a   Haracopos, Demetrious ^b   Knivsberg, Ann Mari ^c   Reichelt, Karl Ludvig ^d   Parlar, Sarah ^b   Jacobsen, Judith ^e   Seim, Anders ^f   Pedersen, Lennart ^b   Schondel, Maja ^b   Shattock, Paul ^a  

^a UNIVERSITY OF SUNDERLAND   (United Kingdom)

^b Center for Autisme   (Denmark)

^c UNIVERSITY OF STAVANGER   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e Statcon ApS   (Denmark)

^f NONE

Author keywords

Adaptive design; Autism spectrum disorder (ASD); Casein; Diet; Gluten; Randomised controlled trial

Indexed keywords

ARTICLE; AUTISM; CASEIN FREE DIET; CHILD; CHILD BEHAVIOR; CHILD NUTRITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; FEMALE; GLUTEN FREE DIET; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

AGING; ATTENTION; CASEINS; CHILD; CHILD DEVELOPMENT; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DIET, GLUTEN-FREE; DIET, PROTEIN-RESTRICTED; FEMALE; GLYCINE; HUMANS; HYPERKINESIS; MALE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; STATISTICS AS TOPIC; TIME FACTORS;

EID: 77951116456     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1179/147683010X12611460763922     Document Type: Article

References (60)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn: text revision (DSM-IV-TR). Washington, DC: APA, 2000.
2. World Health Organization.Mental disorders: a glossary and guide to their classification in accordance with the 10th revision of the international classification of diseases - research diagnostic criteria (ICD-10). Geneva: WHO, 1993.
3. Lee DO, Ousley OY. Attention-deficit hyperactivity disorder symptoms in a clinic sample of children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16: 737-746.
4. Le Couteur A, Bailey A, Goode S et al. A broader phenotype of autism: the clinical spectrum in twins. J Child Psychol Psychiatry 1996; 37: 785-801.
5. Whiteley P. Developmental, behavioural and somatic factors in pervasive developmental disorders: preliminary analysis. Child Care Health Dev 2004; 30: 5-11.
6. Ashwood P, Anthony A, Pellicer AA et al. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol 2003; 23: 504-517.
7. Corbett BA, Kantor AB, Schulman H et al. A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol Psychiatry 2007; 12: 292-306.
8. Baird G, Simonoff E, Pickles A et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006; 368: 210-215.
9. Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics. N Engl J Med 1980; 303: 1336-1342.
10. Reichelt KL, Knivsberg A-M. Can the pathophysiology of autism be explained by the nature of discovered urine peptides? Nutr Neurosci 2003; 6: 19-28.
11. Happé F, Ronald A, Plomin R. Time to give up on a single explanation for autism. Nat Neurosci 2006; 9: 1218-1220.
12. Francis K. Autism interventions: a critical update. Dev Med Child Neurol 2005; 47: 493-499.
13. Knapp M, Romeo R, Beecham J. Economic cost of autism in the UK. Autism 2009; 13: 317-336.
14. Knivsberg A-M, Reichelt KL, Nødland M. Reports on dietary intervention in autistic disorders. Nutr Neurosci 2001; 4: 25-37.
15. Christison GW, Ivany K. Elimination diets in autism spectrum disorders: any wheat amidst the chaff ? J Dev Behav Pediatr 2006; 27: S162-S171.
16. Millward C, Ferriter M, Calver S et al. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 2008; 2: CD003498.
17. McCann D, Barrett A, Cooper A et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. Lancet 2007; 370: 1560-1567.
18. Pelsser LM, Frankena K, Toorman J et al. A randomised controlled trial into the effects of food on ADHD. Eur Child Adolesc Psychiatry 2009; 18: 12-19.
19. Dohan FC, Grassberger JC, Lowell FM et al. Relapsed schizophrenics: more rapid improvement on a milk and cereal free diet. Br J Psychiatry 1969; 115: 595-596.
20. Vlissides DN, Venulet A, Jenner FA. A double-blind glutenfree/ gluten-load controlled trial in a secure ward population. Br J Psychiatry 1986; 148: 447-452.
21. Knivsberg A-M, Wiig K, Lind G et al. Dietary intervention in autistic syndromes. Brain Dysfunct 1990; 3: 315-317.
22. Knivsberg A-M, Reichelt KL, Nødland M et al. Autistic syndromes and diet: a follow-up study. Scand J Educ Res 1995; 39: 223-236.
23. Lucarelli S, Frediani T, Zingoni AM et al. Food allergy and infantile autism. Panminerva Med 1995; 37: 137-141.
24. Whiteley P, Rodgers J, Savery D et al. A gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings. Autism 1999; 3: 45-65.
25. Cade R, Privette M, Fregly M et al. Autism and schizophrenia: intestinal disorders. Nutr Neurosci 2000; 2: 57-72.
26. Reichelt KL, Knivsberg A-M, Lind G et al. Probable etiology and possible treatment of childhood autism. Brain Dysfunct 1991; 4: 308-319.
27. Shattock P, Whiteley P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Ther Targets 2002; 6: 175-183.
28. Knivsberg AM, Reichelt KL, Høien T et al. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci 2002; 5: 251-261.
29. Elder JH, Shankar M, Shuster J et al. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord 2006; 36: 413-420.
30. Cass H, Gringras P, March J et al. Absence of urinary opioid peptides in children with autism. Arch Dis Child 2008; 93: 745-750.
31. Chow SC, Chang M. Adaptive design methods in clinical trials - a review. Orphanet J Rare Dis 2008; 3: 11.
32. Anderson RJ, Bendall DJ, Garnett I et al. Identification of indolyl-3- acryloylglycine (IAG) in the urine of people with autism. J Pharm Pharmacol 2002; 54: 295-298.
33. Solaas KM, Skjeldal O, Gardner MLG et al. Urinary peptides in Rett syndrome. Autism 2002; 6: 315-329.
34. Bull G, Shattock P,Whiteley P et al. Indolyl-3-acryloylglycine (IAG) is a putative diagnostic urinary marker for autism spectrum disorders. Med Sci Monit 2003; 9: CR2-CR5.
35. Carr K, Whiteley P, Shattock P. Development and reproducibility of a novel high-performance liquid-chromatography monolithic column method for the detection and quantification of trans-indolyl-3- acryloylglycine in human urine. Biomed Chromatogr 2009; 23: 1108-1115.
36. Lord C, Risi S, Lambrecht L et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 2000; 30: 205-223.
37. Gilliam JE. Gilliam autism rating scale. Autism, TX: Pro-Ed, 1995.
38. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behaviour Scales (Interview Edition), 2nd edn. Circle Pines, MN: American Guidance Service, 1984.
39. DuPaul GJ, Power TJ, Anastopoulos AD. ADHD rating scale-IV. New York: Guilford, 1998.
40. Boutitie F, Gueyffier F, Pocock SJ, Boissel JP. Assessing treatmenttime interaction in clinical trials with time to event data: a metaanalysis of hypertension trials. Stat Med 1998; 17: 2883-2903.
41. Gotham K, Risi S, Pickles A, Lord C. The Autism Diagnostic Observation Schedule: revised algorithms for improved diagnostic validity. J Autism Dev Disord 2007; 37: 613-627.
42. Howlin P, Asgharian A. The diagnosis of autism and Asperger syndrome: findings from a survey of 770 families. Dev Med Child Neurol 1999; 41: 834-839.
43. Parner ET, Schendel DE, Thorsen P. Autism prevalence trends over time in Denmark: changes in prevalence and age at diagnosis. Arch Pediatr Adolesc Med 2008; 162: 1150-1156.
44. Van Daalen E, Kemner C, Dietz C et al. Inter-rater reliability and stability of diagnoses of autism spectrum disorder in children identified through screening at a very young age. Eur Child Adolesc Psychiatry 2009; 18: 663-674.
45. Gillberg C, Schaumann H. Infantile autism and puberty. J Autism Dev Disord 1981; 11: 365-371.
46. Sandler A. Placebo effects in developmental disabilities: implications for research and practice.Ment Retard Dev Disabil Res Rev 2005; 11: 164-170.
47. Hediger ML, England LJ, Molloy CA et al. Reduced bone cortical thickness in boys with autism or autism spectrum disorder. J Autism Dev Disord 2008; 38: 848-856.
48. Amminger GP, Berger GE, Schäfer MR et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomised, placebo-controlled pilot study. Biol Psychiatry 2006; 61: 551-553.
49. Politi P, Cena H, ComelliMet al. Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Arch Med Res 2008; 39: 682-685.
50. Feinman RD. Intention-to-treat. What is the question? Nutr Metab (Lond) 2009; 6: 1-7.
51. Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009; 19: 227-246.
52. Barnes SA, Mallinckrodt CH, Lindborg SR et al. The impact of missing data and how it is handled on the rate of false-positive results in drug development. Pharm Stat 2008; 7: 215-225.
53. Bakkaloglu B, Anlar B, Anlar FY et al. Atopic features in early childhood autism. Eur J Paediatr Neurol 2008; 12: 476-479.
54. Jyonouchi H. Food allergy and autism spectrum disorders: is there a link? Curr Allergy Asthma Rep 2009; 9: 194-201.
55. Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology 2002; 4: 76-84.
56. Elchaar GM, Maisch NM, Augusto LM et al. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother 2006; 40: 1086-1095.
57. Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses 2009; 72: 333-337.
58. Baron-Cohen S. Autism: research into causes and intervention. Pediatr Rehabil 2004; 7: 73-78.
59. Beauchamp TL, Childress JF. Principles of Biomedical Ethics, 4th edn. Oxford: Oxford University Press, 1994.
60. Hsu CL, Lin CY, Chen CL et al. The effects of a gluten and caseinfree diet in children with autism: a case report. Chang Gung Med J 2009; 32: 459-465.